New and updated respiratory syncytial virus (RSV) resources
Home / News & Opportunities / Latest news / Current post
August 13, 2025
The Australian Government Department of Health, Disability and Aging (the department) has released a number of updated resources to support the correct administration of RSV vaccines and monoclonal antibodies.
A single dose of the RSV vaccine, Abrysvo®, is recommended for women at 28 to 36 weeks of pregnancy and is available for free through the National Immunisation Program (NIP).
- Arexvy® must not be administered to pregnant women.
- Victoria is offering the RSV monoclonal antibody, Beyfortus™ (Nirsevimab) for free to eligible infants and children.
- Abrysvo® and Arexvy® must not be administered to infants or children.
- The department has produced a poster outlining the correct administration of RSV vaccines and monoclonal antibodies by cohort.
Updated resources include:
- RSV vaccine and monoclonal antibody poster – to facilitate appropriate choice of product
- RSV provider advice fact sheet
- RSV consumer advice fact sheet
- RSV frequently asked questions fact sheet.
For more information visit - Respiratory syncytial virus (RSV) vaccine | Australian Government Department of Health, Disability and Ageing
Latest news
The purpose of this activity is to ensure that patients with an active Mental Health Treatment Plan who have not attended the practice in the last six months are identified and followed up, supporting continuity of care and improved mental health outcomes.
Recommendations from healthcare professionals play an important role in parents/guardians’ decisions about childhood vaccination. These recommendations are informed by the National Immunisation Program (NIP) schedule, which outlines the vaccinations recommended for all children in Australia.
A free vaccine to help protect babies against Respiratory Syncytial Virus (RSV) is available for eligible pregnant women in Australia.
